Dry Macular Degeneration: Protect Your Central Vision
Understanding Dry Macular Degeneration
The macula is a tiny area at the center of the retina, the light-sensitive tissue lining the back of the eye. Although the macula is small, it is responsible for your central vision. Central vision is what you use to see fine details, read text, and recognize faces. When the macula is damaged, your side vision may remain intact, but the sharp central vision you rely on most becomes blurred or distorted.
Dry macular degeneration develops when small yellow deposits called drusen accumulate under the retina. Drusen are made up of lipids (fats) and proteins. A few small drusen are normal with aging, but a larger number or larger-sized drusen can indicate early or intermediate AMD. Over time, the light-sensitive cells in the macula thin and break down, a process that gradually reduces central vision.
Retina specialists classify dry AMD into three stages based on the size and number of drusen and any changes to the retinal pigment.
- Early dry AMD: Medium-sized drusen are present. Most people have no noticeable vision loss at this stage.
- Intermediate dry AMD: Large drusen or pigment changes are present. Some people notice mild blurriness in their central vision.
- Late dry AMD (geographic atrophy): Significant loss of light-sensitive cells and supporting tissue in the macula. This stage causes noticeable central vision loss.
There are two forms of age-related macular degeneration. Dry AMD accounts for approximately 80 percent of all AMD cases (National Eye Institute, 2023). In dry AMD, the macula thins gradually over time. Wet AMD is less common but more severe. It occurs when abnormal blood vessels grow under the retina and leak fluid or blood. Dry AMD can progress to wet AMD at any stage, which is why regular monitoring is important.
Who Is Affected and Risk Factors
Age-related macular degeneration is the leading cause of vision loss among people aged 50 and older in the United States (American Academy of Ophthalmology, 2024). Approximately 20 million Americans have some form of AMD, and roughly 12 to 13 million have early or intermediate dry AMD (BrightFocus Foundation, 2024). As the population ages, these numbers are expected to grow.
Age is the strongest risk factor. The condition is most common in people over age 55, and the risk increases significantly after age 65. Genetics also play a major role. People with a family history of AMD are at higher risk. Certain gene variants, particularly in the complement factor H (CFH) gene and the ARMS2 gene, have been linked to a significantly increased risk of developing AMD (National Eye Institute, 2023).
Several modifiable risk factors can influence the development and progression of dry AMD.
- Smoking: Current smokers are two to four times more likely to develop AMD than nonsmokers (American Academy of Ophthalmology, 2024).
- Diet: A diet low in leafy green vegetables, fish, and antioxidant-rich foods may increase risk.
- Obesity: Higher body mass index has been associated with faster progression of AMD.
- Sun exposure: Prolonged exposure to ultraviolet light may contribute to retinal damage over time.
- Cardiovascular disease: High blood pressure and heart disease are associated with increased AMD risk.
Dry AMD is more common in white Americans than in Black, Hispanic, or Asian Americans (National Eye Institute, 2023). Women tend to develop AMD more often than men, in part because women generally live longer. However, anyone can develop the condition regardless of race or gender.
Signs and Symptoms
In its earliest stages, dry macular degeneration often causes no noticeable symptoms. Many people are unaware they have the condition until it is detected during a routine dilated eye exam. As the disease progresses to the intermediate stage, some people begin to notice subtle changes. These may include a slight blurriness in central vision or difficulty seeing in dim lighting.
When dry AMD progresses to geographic atrophy, the late stage, symptoms become more apparent. Central vision may have blank or dark spots. Straight lines may appear wavy or distorted. Colors may seem less vivid. Reading small print becomes difficult even with glasses. These changes typically develop gradually over months or years, though they can sometimes progress more quickly.
Because early dry AMD usually has no symptoms, regular comprehensive eye exams are essential for early detection. The American Academy of Ophthalmology recommends baseline eye exams at age 40 and more frequent exams after age 65 (AAO, 2024). People with known risk factors may need exams more often. Early detection gives your retina specialist the best opportunity to monitor changes and recommend steps to slow progression.
Diagnosis and Testing
A dilated eye exam is the standard method for diagnosing dry macular degeneration. During this exam, drops are placed in the eyes to widen the pupils. This allows a retina specialist to view the macula directly and look for drusen, pigment changes, or areas of atrophy. A dilated exam is painless and provides detailed information about the health of the retina.
Optical coherence tomography, known as OCT, is a noninvasive imaging test that creates detailed cross-sectional images of the retina. It can measure the thickness of the retina and detect drusen, fluid, or thinning of retinal layers that may not be visible during a standard exam. OCT is one of the most important tools retina specialists use to monitor AMD progression over time.
Fundus autofluorescence (FAF) imaging uses a special camera to detect metabolic changes in the retinal pigment epithelium, the layer of cells beneath the retina. It is particularly useful for mapping the boundaries of geographic atrophy. Fundus photography captures high-resolution color images of the retina to document changes between visits. Both tests help retina specialists track the condition precisely.
An Amsler grid is a simple tool you can use at home to monitor your central vision. It consists of a grid of straight lines with a dot in the center. You cover one eye, focus on the center dot, and note whether any lines appear wavy, blurry, or missing. Changes in the grid pattern should be reported to your retina specialist promptly, as they may indicate progression or a conversion to wet AMD.
Treatment Options
The Age-Related Eye Disease Studies (AREDS and AREDS2) are landmark clinical trials conducted by the National Eye Institute. AREDS2 found that a specific combination of vitamins and minerals reduced the risk of progressing from intermediate to late AMD by approximately 25 percent (NEI, 2013). The AREDS2 formula includes vitamin C, vitamin E, lutein, zeaxanthin, zinc, and copper. These supplements are available over the counter. Your retina specialist can advise whether the AREDS2 formula is appropriate for your stage of dry AMD.
It is important to note that AREDS2 supplements are not a cure. They do not reverse existing damage or improve vision that has been lost. They are recommended specifically for people with intermediate dry AMD or late AMD in one eye to help slow further progression.
For the first time, there are FDA-approved treatments specifically for geographic atrophy, the advanced stage of dry AMD. Syfovre (pegcetacoplan), a complement inhibitor, was approved by the FDA in February 2023. Izervay (avacincaptad pegol), another complement inhibitor, was approved in August 2023. Both medications work by targeting the complement system, a part of the immune system that contributes to the destruction of retinal cells in geographic atrophy.
Syfovre is administered as an intravitreal injection (an injection into the eye) every 25 to 60 days. Izervay is given as an intravitreal injection once per month. Clinical trials showed that both treatments significantly reduced the rate of geographic atrophy growth compared to no treatment (FDA, 2023). These medications do not restore vision that has been lost, but they can slow the expansion of atrophy and may help preserve remaining vision.
Lifestyle changes can play a meaningful role in managing dry AMD. The following steps are supported by clinical evidence.
- Stop smoking: Quitting smoking is one of the most effective steps to reduce AMD risk and slow progression.
- Eat a nutrient-rich diet: Foods high in lutein and zeaxanthin, such as kale, spinach, and eggs, support macular health. Omega-3 fatty acids found in fish may also be beneficial.
- Exercise regularly: Moderate physical activity has been linked to lower AMD risk.
- Protect your eyes from UV light: Wear sunglasses that block both UVA and UVB rays when outdoors.
- Manage cardiovascular health: Controlling blood pressure and cholesterol supports overall eye health.
For people who have experienced significant central vision loss from advanced dry AMD, low vision rehabilitation can help maximize remaining vision. Low vision specialists can recommend tools such as magnifying glasses, large-print materials, screen readers, and specialized lighting. These aids can help people continue to read, use computers, and maintain independence. Your retina specialist can provide a referral to low vision services.
What to Expect
Dry macular degeneration is a chronic, progressive condition. In many people, it progresses slowly over years or even decades. Some individuals with early dry AMD may never progress beyond that stage. Others may advance to intermediate or late AMD. The rate of progression varies widely from person to person and depends on factors such as genetics, lifestyle, and the specific characteristics of drusen.
Regular follow-up visits with a retina specialist are essential for managing dry AMD. The frequency of visits depends on the stage of the disease. People with early AMD may be seen once a year. Those with intermediate or advanced AMD may need visits every three to six months. During each visit, your retina specialist will perform imaging tests to check for any changes, including signs of progression to geographic atrophy or conversion to wet AMD.
A diagnosis of macular degeneration can feel overwhelming. Concerns about losing independence or the ability to drive and read are common and valid. It is important to know that most people with dry AMD retain useful vision for many years, especially with proper monitoring and management. Support groups, counseling, and low vision services can help you adapt and maintain quality of life.
Living With Dry Macular Degeneration
Small adjustments to your daily routine can make a significant difference. Increasing lighting in your home, especially for reading and detail work, can help. Using large-print books or e-readers with adjustable font sizes makes reading easier. High-contrast settings on phones and computers improve screen visibility. Organizing your home to reduce tripping hazards protects your safety.
Using an Amsler grid at home between appointments is a simple but important habit. Check each eye separately, once a day, in good lighting. If you notice any new waviness, blurriness, or missing areas in the grid, contact your retina specialist right away. These changes could signal progression to wet AMD, which requires urgent treatment to prevent rapid vision loss.
Dry AMD does not have to prevent you from living a full life. Many people continue to work, socialize, travel, and enjoy hobbies. Audiobooks, voice-activated technology, and adaptive devices make many activities accessible even with reduced central vision. Staying physically and socially active is good for both your overall health and your emotional well-being.
When to See a Retina Specialist
Anyone over age 50 should have regular comprehensive eye exams that include evaluation of the macula. If you have a family history of AMD, smoking history, or other risk factors, talk to your eye care provider about more frequent screening. Early detection of dry AMD is critical because treatments and preventive measures are most effective in the earlier stages.
Certain vision changes require urgent evaluation. See a retina specialist or go to the emergency room immediately if you experience any of the following symptoms.
- A sudden increase in floaters (spots or cobwebs drifting across your vision)
- Flashes of light in one or both eyes
- A dark curtain or shadow moving across your field of vision
- Sudden blurring or loss of central vision
- Sudden distortion where straight lines appear wavy
These symptoms could indicate a conversion from dry to wet AMD or another serious retinal condition. Prompt treatment can help prevent permanent vision loss.
Questions and Answers
Currently, there is no treatment that can reverse dry macular degeneration or restore vision that has been lost. However, AREDS2 nutritional supplements can slow progression in people with intermediate AMD. The newly approved complement inhibitors Syfovre (pegcetacoplan) and Izervay (avacincaptad pegol) can slow the growth of geographic atrophy. Research into new treatments is ongoing, and early detection combined with proactive management gives the best chance of preserving vision.
If you have geographic atrophy and your retina specialist recommends treatment with a complement inhibitor, the injection schedule depends on the specific medication. Syfovre (pegcetacoplan) is given every 25 to 60 days. Izervay (avacincaptad pegol) is given once per month. Your retina specialist will determine the best schedule for your situation. These injections are performed in the office and take only a few minutes.
Most people with dry macular degeneration do not go completely blind. AMD primarily affects central vision, but peripheral (side) vision is typically preserved. Even in advanced stages, most people retain enough peripheral vision to navigate their environment and maintain a degree of independence. Low vision aids and rehabilitation services can help maximize the vision you have.
The AREDS2 formula is generally well tolerated, but it is not appropriate for everyone. The original AREDS formula contained beta-carotene, which was linked to an increased risk of lung cancer in current and former smokers. The updated AREDS2 formula replaced beta-carotene with lutein and zeaxanthin, making it safer. You should discuss any supplement use with your retina specialist and primary care provider, especially if you take other medications or have other health conditions.
Drusen are small yellow deposits that accumulate under the retina. They are a hallmark of early and intermediate dry AMD. Having drusen does not necessarily mean you will lose vision, but their size and number help predict your risk of progression. Geographic atrophy is the advanced stage of dry AMD where retinal cells and the supporting tissue beneath them have been lost. This cell loss creates permanent areas of central vision loss. Geographic atrophy develops from long-standing dry AMD, and it is the stage where complement inhibitor treatments may be recommended.